HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (25) Citing Articles via Google Scholar Google Scholar Articles by O’Donnell, D. E. Search for Related Content PubMed PubMed Citation Articles by O’Donnell, D. E.

Assessment of Bronchodilator Efficacy in Symptomatic COPD^*

Is Spirometry Useful?

^* From the Respiratory Investigation Unit, Department of Medicine, Queen’s University, Kingston, Ontario, Canada.

Correspondence to: Denis E. O’Donnell MD, FCCP, Richardson House, 102 Stuart St, Kingston, Ontario, Canada K7L 2V6; e-mail: odonnell{at}post.queensu.ca

Bronchodilator therapy in COPD is deemed successful if it improves ventilatory mechanics to a degree where effective symptom alleviation and increased exercise capacity are achieved. A greater understanding of the pathophysiologic mechanisms of dyspnea and exercise intolerance in COPD has prompted a reevaluation of the manner in which we currently assess therapeutic efficacy. The traditional reliance on an improved postbronchodilator FEV₁ as indicative of a positive clinical response has recognized limitations. To the extent that pharmacologic volume reduction is a desirable therapeutic goal with favorable implications for dyspnea relief and increased exercise tolerance, the potential value of bronchodilator-induced changes in lung volume measurements is currently being studied. It is unlikely, however, given the multifactorial nature of dyspnea and exercise limitation in COPD, that resting spirometric measurements of maximal flows and volumes alone will be sufficiently sensitive to adequately predict a positive clinical response to bronchodilator therapy. Thus, additional direct measurements of exercise dynamic hyperinflation and exercise endurance together with reliable subjective measurements of dyspnea and quality of life are recommended in the setting of a suitable placebo-controlled design.

Key Words: bronchodilators • COPD • dyspnea • exercise • inspiratory capacity • lung hyperinflation • spirometry

This article has been cited by other articles:

				A. O. D'Souza, M. J. Smith, L. A. Miller, and J. Kavookjian An Appraisal of Pharmacoeconomic Evidence of Maintenance Therapy for COPD Chest, June 1, 2006; 129(6): 1693 - 1708. [Abstract] [Full Text] [PDF]

				R. Pellegrino, G. Viegi, V. Brusasco, R. O. Crapo, F. Burgos, R. Casaburi, A. Coates, C. P. M. van der Grinten, P. Gustafsson, J. Hankinson, et al. Interpretative strategies for lung function tests Eur. Respir. J., November 1, 2005; 26(5): 948 - 968. [Full Text] [PDF]

				N. J. Gross Chronic Obstructive Pulmonary Disease Outcome Measurements: What's Important? What's Useful? Proceedings of the ATS, November 1, 2005; 2(4): 267 - 271. [Abstract] [Full Text] [PDF]

				S. I. Rennard and J. A. Stoner Challenges and Opportunities for Combination Therapy in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 391 - 393. [Abstract] [Full Text] [PDF]

				B. Celli, R. ZuWallack, S. Wang, and S. Kesten Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes Chest, November 1, 2003; 124(5): 1743 - 1748. [Abstract] [Full Text] [PDF]

				R. Duranti, M. Filippelli, R. Bianchi, I. Romagnoli, R. Pellegrino, V. Brusasco, and G. Scano Inspiratory Capacity and Decrease in Lung Hyperinflation With Albuterol in COPD Chest, December 1, 2002; 122(6): 2009 - 2014. [Abstract] [Full Text] [PDF]

				A. Corsico, P. Fulgoni, M. Beccaria, M. C. Zoia, G. Barisione, R. Pellegrino, V. Brusasco, and I. Cerveri Effects of exercise and beta 2-agonists on lung function in chronic obstructive pulmonary disease J Appl Physiol, December 1, 2002; 93(6): 2053 - 2058. [Abstract] [Full Text] [PDF]

				R. Aalbers, J. Ayres, V. Backer, M. Decramer, P.A. Lier, P. Magyar, J. Malolepszy, R. Ruffin, and G.W. Sybrecht Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Eur. Respir. J., May 1, 2002; 19(5): 936 - 943. [Abstract] [Full Text] [PDF]

				B. J. Lipworth Optimizing Bronchodilator Therapy for COPD Chest, June 1, 2001; 119(6): 1628 - 1630. [Full Text] [PDF]

				R. L. ZuWallack, D. A. Mahler, D. Reilly, N. Church, A. Emmett, K. Rickard, and K. Knobil Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD Chest, June 1, 2001; 119(6): 1661 - 1670. [Abstract] [Full Text] [PDF]

				P. M. A. Calverley The Future for Tiotropium Chest, February 1, 2000; 117(2_suppl): 67S - 69S. [Abstract] [Full Text] [PDF]